Drawing for BRIDGE TO EUROPE

USPTO serial 88718577

BRIDGE TO EUROPE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
REID, CAILE MAUREEN
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BRIDGE TO EUROPE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Richard M. LaBarge

Richard M. LaBarge MARSHALL, GERSTEIN & BORUN LLP233 SOUTH WACKER DRIVE, SUITE 6300CHICAGO, IL 60606UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
009Downloadable and recorded computer software for use as a database and for analysing data in the fields of pharmaceuticals, clinical trials, clinical research and biotechnology; Downloadable software applications for computers, laptops and mobile phones featuring software for use as a database and for collating, storing, analysing, and utilizing data in the fields of pharmaceuticals, clinical trials, clinical research and biotechnology; Downloadable and recorded software for secure data storage and retrieval and transmission of customer and client information; Downloadable and recorded computer software for use as a database and for collating, storing, analysing and utilizing data in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; downloadable and recorded computer operating programs and downloadable and recorded application development software for use on or in connection with mobile phones, tablets and handheld devices in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; data processing equipment and computers; Downloadable electronic publications in the nature of e-books, magazines, newsletters and reports provided on-line from a database or the internet in the fields of pharmaceuticals, clinical trials, clinical research and biotechnologyACTIVE—
035Business project and risk management services in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; business consultancy services; Business project and risk management and consultancy services in the field of clinical trials and clinical research; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management services for medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; providing business information management services on clinical trials and clinical research; providing business intelligence services in the fields of medical devices, pharmaceuticals and the life sciences; providing business management information in connection with consultancy and advisory services in the field of strategic planning; regulatory submission management, namely, business strategic planning, and preparing and submitting applications for others for new medical devices, new pharmaceuticals, variations on previously approved medical devices, and variations on previously approved pharmaceuticals to receive clinical trial approval or marketing authorization from governmental regulatory bodies; regulatory submission management, namely, assisting others with strategic business planning, and preparing and filing applications with governmental regulatory bodies for approval of new medical devices and new pharmaceuticals; Regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; New pharmaceutical and biotechnology product commercialization services; consultancy services for others in the field of new pharmaceutical and biotechnology product commercialization; information, advice and consultancy services in relation to all the aforesaid servicesACTIVE—
038Providing Internet access, namely, providing access to platforms and portals on the internet in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; providing user access to global computer networks, namely, providing user access platforms and portals on the internet in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; information, advice and consultancy services in relation to all the aforesaid servicesACTIVE—
042Providing medical and scientific research information in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; Product and scientific research and development in the field of pharmaceuticals, clinical trials, clinical research, medical devices and biotechnology; Consultancy services for others in the field of technical consultancy for pharmaceuticals, design, planning, and implementation consultancy for clinical trials, consultancy on scientific clinical research, and design and development consultancy for medical devices; conducting early evaluations in the field of new pharmaceuticals; consultancy services in the field of design, planning, implementation and project management of clinical trials, pharmacovigilance, pharmaceutical and biotechnology product development; consultancy services in the fields of biotechnology, pharmaceutical research and development, laboratory testing and pharmacogenetics; medical and scientific research; conducting clinical trials for others; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; product development consultancy in the field of pharmaceuticals and biotechnology; testing and quality control evaluation of products in the field of pharmaceuticals, clinical trials and biotechnology; product testing and quality control evaluation of pharmaceutical preparations and medicines; testing and quality control in the nature of conducting clinical trials in the field of pharmaceuticals and biotechnology for others; Software as a Service (SaaS) featuring software for use as a database and for analysing data in the fields of in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; providing online non-downloadable software applications for use in creating, designing, hosting, publishing, managing and maintaining content for use on the internet for website and media content management purposes; application service provider featuring application programming interface (API) software to allow people to view data through an interactive map, to query data, to generate reports and to access data and documents; software as a service (SAAS) featuring computer software to enable the displaying, receiving and transmitting of data to enable the purchase of goods and services; information, advice and consultancy services in relation to all the aforesaid servicesACTIVE—
044Managed healthcare services being medical services in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; consultancy services in the field of medical information services; medical consultancy services in the field of pharmaceuticals, clinical trials, clinical research and biotechnology; consultancy services in the field of biotechnology diagnostics and pharmacogenetics diagnostics medical testing; medical information, advice and consultancy services in the pharmaceutical and healthcare sectors; medical information, advice and consultancy services in relation to pharmacovigilance; information, advice and consultancy services in relation to all the aforesaid servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Nov 22, 2021MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 22, 2021ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 20, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 23, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 23, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 3, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 21, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 21, 2021XAECEXAMINER'S AMENDMENT ENTERED—
Jan 21, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 21, 2021GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 21, 2021CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 19, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 19, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 19, 2021ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Sep 29, 2020GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Sep 29, 2020GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 29, 2020CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 3, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 3, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 3, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 9, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 9, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 9, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 6, 2020DOCKASSIGNED TO EXAMINER—
Dec 11, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 10, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance